These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

658 related articles for article (PubMed ID: 11689649)

  • 1. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses.
    Pushko P; Geisbert J; Parker M; Jahrling P; Smith J
    J Virol; 2001 Dec; 75(23):11677-85. PubMed ID: 11689649
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA vaccines elicit durable protective immunity against individual or simultaneous infections with Lassa and Ebola viruses in guinea pigs.
    Cashman KA; Wilkinson ER; Wollen SE; Shamblin JD; Zelko JM; Bearss JJ; Zeng X; Broderick KE; Schmaljohn CS
    Hum Vaccin Immunother; 2017 Dec; 13(12):3010-3019. PubMed ID: 29135337
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates.
    Hevey M; Negley D; Pushko P; Smith J; Schmaljohn A
    Virology; 1998 Nov; 251(1):28-37. PubMed ID: 9813200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replicon-helper systems from attenuated Venezuelan equine encephalitis virus: expression of heterologous genes in vitro and immunization against heterologous pathogens in vivo.
    Pushko P; Parker M; Ludwig GV; Davis NL; Johnston RE; Smith JF
    Virology; 1997 Dec; 239(2):389-401. PubMed ID: 9434729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus.
    Pushko P; Bray M; Ludwig GV; Parker M; Schmaljohn A; Sanchez A; Jahrling PB; Smith JF
    Vaccine; 2000 Aug; 19(1):142-53. PubMed ID: 10924796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.
    Wang M; Jokinen J; Tretyakova I; Pushko P; Lukashevich IS
    Vaccine; 2018 Jan; 36(5):683-690. PubMed ID: 29287681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation in nonhuman primates of vaccines against Ebola virus.
    Geisbert TW; Pushko P; Anderson K; Smith J; Davis KJ; Jahrling PB
    Emerg Infect Dis; 2002 May; 8(5):503-7. PubMed ID: 11996686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progress in recombinant DNA-derived vaccines for Lassa virus and filoviruses.
    Grant-Klein RJ; Altamura LA; Schmaljohn CS
    Virus Res; 2011 Dec; 162(1-2):148-61. PubMed ID: 21925552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins.
    Wilson JA; Bray M; Bakken R; Hart MK
    Virology; 2001 Aug; 286(2):384-90. PubMed ID: 11485406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bivalent Junin & Machupo experimental vaccine based on alphavirus RNA replicon vector.
    Johnson DM; Jokinen JD; Wang M; Pfeffer T; Tretyakova I; Carrion R; Griffiths A; Pushko P; Lukashevich IS
    Vaccine; 2020 Mar; 38(14):2949-2959. PubMed ID: 32111526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vesicular stomatitis virus-based vaccines against Lassa and Ebola viruses.
    Marzi A; Feldmann F; Geisbert TW; Feldmann H; Safronetz D
    Emerg Infect Dis; 2015 Feb; 21(2):305-7. PubMed ID: 25625358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alphavirus DNA and particle replicons for vaccines and gene therapy.
    Polo JM; Gardner JP; Ji Y; Belli BA; Driver DA; Sherrill S; Perri S; Liu MA; Dubensky TW
    Dev Biol (Basel); 2000; 104():181-5. PubMed ID: 11713818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig Model.
    Kainulainen MH; Spengler JR; Welch SR; Coleman-McCray JD; Harmon JR; Klena JD; Nichol ST; Albariño CG; Spiropoulou CF
    J Infect Dis; 2018 May; 217(12):1957-1966. PubMed ID: 29800368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses.
    Reed DS; Glass PJ; Bakken RR; Barth JF; Lind CM; da Silva L; Hart MK; Rayner J; Alterson K; Custer M; Dudek J; Owens G; Kamrud KI; Parker MD; Smith J
    J Virol; 2014 Oct; 88(20):12077-86. PubMed ID: 25122801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
    Wang D; Raja NU; Trubey CM; Juompan LY; Luo M; Woraratanadharm J; Deitz SB; Yu H; Swain BM; Moore KM; Pratt WD; Hart MK; Dong JY
    J Virol; 2006 Mar; 80(6):2738-46. PubMed ID: 16501083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection.
    Schleiss MR; Lacayo JC; Belkaid Y; McGregor A; Stroup G; Rayner J; Alterson K; Chulay JD; Smith JF
    J Infect Dis; 2007 Mar; 195(6):789-98. PubMed ID: 17299708
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective cytotoxic T-cell responses induced by venezuelan equine encephalitis virus replicons expressing Ebola virus proteins.
    Olinger GG; Bailey MA; Dye JM; Bakken R; Kuehne A; Kondig J; Wilson J; Hogan RJ; Hart MK
    J Virol; 2005 Nov; 79(22):14189-96. PubMed ID: 16254354
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever.
    Sun Y; Li HY; Tian DY; Han QY; Zhang X; Li N; Qiu HJ
    Vaccine; 2011 Oct; 29(46):8364-72. PubMed ID: 21888938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protection of guinea pigs from Lassa fever by vaccinia virus recombinants expressing the nucleoprotein or the envelope glycoproteins of Lassa virus.
    Morrison HG; Bauer SP; Lange JV; Esposito JJ; McCormick JB; Auperin DD
    Virology; 1989 Jul; 171(1):179-88. PubMed ID: 2741340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.
    Safronetz D; Mire C; Rosenke K; Feldmann F; Haddock E; Geisbert T; Feldmann H
    PLoS Negl Trop Dis; 2015 Apr; 9(4):e0003736. PubMed ID: 25884628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.